Iveric Bio Inc - ESG Rating & Company Profile powered by AI
This ESG rating includes seventeen United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Reduced Inequalities' and 'Life on Land'. Full ESG analysis of Iveric Bio Inc can be accessed by signing up for free. The webpage of Iveric Bio Inc was prepared by All Street Sevva using proprietary machine learning.
Iveric Bio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.5; made up of an environmental score of 1.6, social score of 1.6 and governance score of 4.0.
2.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 1954 | Vaxcell Bio Therapeutics | 2.6 | Medium |
| 1954 | Zhejiang Starry Pharmaceutical Co Ltd | 2.6 | Medium |
| 1976 | Iveric Bio Inc | 2.5 | Medium |
| 1976 | Chemon Inc | 2.5 | Medium |
| 1976 | Chengdu Kanghong Pharmaceutical Group Co Ltd | 2.5 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Iveric Bio Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Iveric Bio Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Iveric Bio Inc report the average age of the workforce?
Sign up for free to unlockDoes Iveric Bio Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Iveric Bio Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Iveric Bio Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Iveric Bio Inc offer flexible work?
Sign up for free to unlockDoes Iveric Bio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Iveric Bio Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Iveric Bio Inc conduct supply chain audits?
Sign up for free to unlockDoes Iveric Bio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Iveric Bio Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Iveric Bio Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Iveric Bio Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Iveric Bio Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Iveric Bio Inc disclose water use targets?
Sign up for free to unlockDoes Iveric Bio Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Iveric Bio Inc have a product recall in the last two years?
Sign up for free to unlockDoes Iveric Bio Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Iveric Bio Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Iveric Bio Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Iveric Bio Inc disclose parental leave metrics?
Sign up for free to unlockDoes Iveric Bio Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Iveric Bio Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Iveric Bio Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Iveric Bio Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Iveric Bio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Iveric Bio Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Iveric Bio Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Iveric Bio Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Iveric Bio Inc disclose its waste policy?
Sign up for free to unlockDoes Iveric Bio Inc report according to TCFD requirements?
Sign up for free to unlockDoes Iveric Bio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Iveric Bio Inc disclose energy use targets?
Sign up for free to unlockDoes Iveric Bio Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Iveric Bio Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Iveric Bio Inc
These potential risks are based on the size, segment and geographies of the company.
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.